Medical News Today, Article Date: 17 Jul 2010
"EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB)"
"EPO-driven neuroprotection in human brain disorders is now possible with systemic administration of the HIRMAb-EPO fusion protein at doses that have minimal effects on erythropoiesis."
ArmaGen® Web
Sunday, July 18, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment